Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
517
datasets available to search
ShareScore release 0.9.0
Dataset results
517 results for “Checkpoint inhibitors”
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
Open the record for dataset details and reuse information.
Biomarkers in Metastatic Castration-Resistant Prostate Cancer for efficiency of Immune Checkpoint Inhibitors
Open the record for dataset details and reuse information.
Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome
<p>This repository contains supplementary materials for the research paper "Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome". The materials are organized in the following folders:</p> <ul> <li>01_code: code to reproduce the results</li> <li>02_raw_data_public: raw gene count data of the 14,085 whole blood transcriptomes from public datasets (PUBLIC)</li> <li>03_raw_data_primero: raw gene count data of the 145 pre-ICI whole blood samples from the PRIMERO cohort, including sample annotation with response data ("primero_sample_anno.tsv")</li> <li>04_ica: results of the independent component analysis on the PUBLIC dataset, including the transcriptional components ("ica_public_flipped_consensus_independent_components.tsv"), the gene set enrichment analysis results on these components, and the projected activities of the PRIMERO samples for these transcriptional components ("ica_primero_mixing_matrix_projected_corrected.tsv")<br><br></li> </ul>
Immune signatures predict development of autoimmune toxicity in immune checkpoint inhibitor-treated patients with cancer
<p><strong>Immune signatures predict development of autoimmune toxicity in immune</strong><strong> checkpoint inhibitor-treated patients with cancer</strong></p> <p> </p> <p>Nicolas Gonzalo Nuñez<sup>1</sup>*, Fiamma Berner<sup>2</sup>*, Ekaterina Friebel<sup>1</sup>*, Susanne Unger<sup>1</sup>, Nina Wyss<sup>2,3</sup>, Julia Martinez Gomez<sup>4</sup>, Mette-Triin Purde<sup>2</sup>, Rebekka Niederer<sup>2,3</sup>, Maximilian Porsch<sup>5</sup>, Christa Lichtensteiger<sup>2</sup>, Rafaela Kramer<sup>6</sup>, Michael Erdmann<sup>6</sup>, Christina Schmitt<sup>7</sup>, Lucy Heinzerling<sup>6,7</sup>, Marie-Therese Abdou<sup>2</sup>, Julia Karbach<sup>8</sup>, Dirk Schadendorf<sup>9</sup>, Lisa Zimmer<sup>9</sup>, Selma Ugurel<sup>9</sup>, Niklas Klümper<sup>10,11,12</sup>, Michael Hölzel<sup>10,11</sup>, Laura Power<sup>1</sup>, Stefanie Kreutmair<sup>1</sup>, Mariaelena Capone<sup>13</sup>, Gabriele Madonna<sup>13</sup>, Lacin Cevhertas<sup>14,15</sup>, Anja Heider<sup>14</sup>, Teresa Amaral<sup>16,17</sup>, Omar Hasan Ali<sup>2,3,4,18</sup>, David Bomze<sup>2,19</sup>, Florentia Dimitriou<sup>4</sup>, Stefan Diem<sup>20</sup>, Paolo Antonio Ascierto<sup>13</sup>, Reinhard Dummer<sup>4</sup>, Elke Jäger<sup>8</sup>, Christoph Driessen<sup>20</sup>, Mitchell P. Levesque<sup>4</sup>, Willem van de Veen<sup>14</sup>, Markus Joerger<sup>20</sup>, Martin Früh<sup>20,21</sup>, Burkhard Becher<sup>1</sup>**, Lukas Flatz<sup>2,3,4,20,22</sup>**</p> <p> </p> <p>*/** these authors contributed equally</p> <p> Affiliations</p> <p>1. Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland</p> <p>2. Institute of Immunobiology, Medical Research Center, Kantonsspital St. Gallen, St.Gallen, Switzerland</p> <p>3. Department of Dermatology, Kantonsspital St. Gallen, St.Gallen, Switzerland</p> <p>4. Department of Dermatology, University Hospital Zurich, Zurich, Switzerland</p> <p>5. Department of Radiology, Kantonsspital St. Gallen, St.Gallen, Switzerland</p> <p>6. Department of Dermatology, University of Erlangen-Nuremberg, Erlangen, Germany</p> <p>7. Ludwig Maximilian University of Munich, Munich, Germany</p> <p>8. Department of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany</p> <p>9. Department of Dermatology, Comprehensive Cancer Center (Westdeutsches Tumorzentrum) University Hospital Essen, Essen, Germany</p> <p>10. Institute for Experimental Oncology, University Hospital Bonn, Bonn, Germany</p> <p>11. Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, Bonn, Germany</p> <p>12. Department of Urology, University Hospital Bonn, Bonn, Germany</p> <p>13. Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italy</p> <p>14. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</p> <p>15. Department of Medical Immunology, Institute of Health Sciences, Bursa Uludag University, Bursa, Turkey</p> <p>16. Skin Cancer Center, Department of Dermatology, University Hospital Tübingen, Tübingen, Germany</p> <p>17. iFIT Cluster of Excellence (EXC 2180), University of Tübingen, Tübingen, Germany</p> <p>18. Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada</p> <p>19. Sackler Faculty of Medicine, Tel-Aviv University, Israel</p> <p>20. Department of Oncology, Kantonsspital St. Gallen, St.Gallen, Switzerland</p> <p>21. Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland</p> <p>22. Universitäts-Hautklinik, University of Tübingen, Tübingen, Germany</p> <p> </p> <p> </p>
Single cell data from Imaging Mass Cytometry of mouse lung tumours treated with KRAS-G12C and immune checkpoint inhibitors (Dataset 3)
Open the record for dataset details and reuse information.
Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Ad-vanced and Metastatic Esophageal Squamous Cell Carcinoma: a real world experience
<p><strong>Figure S1 the detail of treatments.</strong> Blue arrow means this patient was still alive at the latest date of follow up. Hollow circle means this patient die. The others were lose follow up at the latest date of follow up.</p> <p><strong>Figure S2 progression free survival (PFS) of patients received immunotherapy, including 5 nivolumab and chemotherapy and 1 dual immune check point inhibitor, on different PD-L1 tumor cells (TC) expression.</strong> (A) divided by PD-L1 TC <1% or ≧1%. (B)divided by PD-L1 TC <10% or ≧10%.</p>
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
ClinicalTrials.gov study NCT06349642. IPD Sharing: NO. Countries: 1. Publications: 1.
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor
ClinicalTrials.gov study NCT06218069. IPD Sharing: NO. Countries: 2. Publications: 11.
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
ClinicalTrials.gov study NCT04957160. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
ClinicalTrials.gov study NCT03775850. IPD Sharing: NO. Countries: 2. Publications: 1.
Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors
ClinicalTrials.gov study NCT05699915. IPD Sharing: NO. Countries: 1. Publications: 1.
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
ClinicalTrials.gov study NCT06522048. IPD Sharing: NO. Countries: 1. Publications: 5.
Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors
ClinicalTrials.gov study NCT06470997. IPD Sharing: Not stated. Countries: 1. Publications: 9.
Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume
ClinicalTrials.gov study NCT04430712. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor
ClinicalTrials.gov study NCT03590808. IPD Sharing: NO. Countries: 1. Publications: 9.
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers
ClinicalTrials.gov study NCT04196465. IPD Sharing: Not stated. Countries: 1. Publications: 0.
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
ClinicalTrials.gov study NCT04294771. IPD Sharing: NO. Countries: 1. Publications: 7.
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
ClinicalTrials.gov study NCT05334329. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
ClinicalTrials.gov study NCT02723006. IPD Sharing: YES. Countries: 1. Publications: 0.
Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms
ClinicalTrials.gov study NCT03601611. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.